Diagnostic testing is becoming even more essential to quality healthcare. Demographic transitions under way in our markets — from growing prosperity to increasing incidence of chronic disease — are the driving forces behind rising demand for better healthcare in large segments of the populations.
Consistent with IDH’s aim to make modern medical diagnostics more accessible to the most resource-poor populations, the Group seeks to play a central role in improving health outcomes in all the emerging markets in which it operates. In 2023, the Company performed 36.1 million diagnostic tests serving 8.5 million patients through a branch network of 601 laboratories spanning Egypt, Jordan, Sudan, and Nigeria.
IDH offers more than 3,000 diagnostic pathology tests ranging from routine to advanced. Common tests include those for cholesterol, diabetes, pregnancy and substance abuse; whilst specialized tests would be performed as part of genetics, immunology, oncology and endocrinology diagnoses.
In 2018, the company launched its radiology service offering. Through Al Borg Scan, it now offers a full range of radiology services, including but not limited to magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography – computed tomography (PET-CT), electromyography (EMG), electrocardiogram (ECG), electroencephalogram (EEG), ultrasound, x-ray, mammograms and cath lab facilities.